The global market for Advanced Therapy Medicinal Products is estimated at US$10.8 Billion in 2023 and is projected to reach US$24.0 Billion by 2030, growing at a CAGR of 12.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs.
Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.
The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs.
Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market's growth.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Tissue Engineered Products segment, which is expected to reach US$10.0 Billion by 2030 with a CAGR of a 12.9%. The Cell Therapy segment is also set to grow at 11.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $4.8 Billion in 2023, and China, forecasted to grow at an impressive 10.5% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Advanced Therapy Medicinal Products Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Advanced Therapy Medicinal Products Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Advanced Therapy Medicinal Products Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Bluebird Bio Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 190 Featured):
- Bluebird Bio Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- JCR Pharmaceuticals Co. Ltd.
- Kolon TissueGene, Inc.
- MEDIPOST Co., Ltd.
- Novartis AG
- Organogenesis Inc.
- Spark Therapeutics, Inc.
- UniQure N.V.
- Vericel Corporation
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bluebird Bio Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- JCR Pharmaceuticals Co. Ltd.
- Kolon TissueGene, Inc.
- MEDIPOST Co., Ltd.
- Novartis AG
- Organogenesis Inc.
- Spark Therapeutics, Inc.
- UniQure N.V.
- Vericel Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 436 |
| Published | October 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 10.8 Billion |
| Forecasted Market Value ( USD | $ 24 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
